In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

Lupin is introducing rivaroxaban tablets, 2.5 mg to the market. The drug is also indicated to reduce the risk of major thrombotic vascular events in adult patients with peripheral artery disease ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

macOS Sequoia has been available for compatible Macs since September 2024, but further updates to Sequoia are expected over the next few months, with the latest major update being macOS 15.3 ...

“Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA, ...

The approval is only for the 2.5mg tablet. Xarelto is also available in 10mg, 15mg, and 20mg tablets, as well as an oral suspension (1mg/mL), to treat various conditions. In a statement, the FDA noted ...

On Friday, Lupin launched rivaroxaban tablets USP, 2.5 mg, in the US market. This was followed after the final approval from the US Food and Drug Administration (US FDA) for its abbreviated new ...

Citi said the company's announcement of generic Rivaroxaban 2.5 mg (Xarelto 2.5mg) tablets in the US is an "at risk" launch as the patent litigation is still ongoing. The patent will expire in 2039.

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. The medication is used to reduce the risk of major cardiovascular events in patients with coronary ...